Perfusion-Phase [(18)F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration

灌注期 [(18)F]THK5351 Tau-PET 成像作为神经退行性疾病的替代标志物

阅读:1

Abstract

We aimed to test if early, perfusion phase tau-PET imaging with [(18)F]THK5351 might substitute for [(18)F]FDG PET information on neurodegeneration, as has been previously shown for amyloid-tracers. A patient with cognitive impairment and positive amyloid-PET was examined by [(18)F]THK5351 tau-PET and [(18)F]FDG PET. The pattern of early phase of [(18)F]THK5351 uptake was compared to [(18)F]FDG visually and by the dice similarity coefficient. Visual inspection of axial slices and stereotactic-surface projection indicated a striking agreement between combined 0-2 min p.i. perfusion images of [(18)F]THK5351 and standard [(18)F]FDG 30-60 min p.i. A two-phase protocol of [(18)F]THK5351 PET might give information on neurodegeneration and tau pathology in a single session.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。